Publication:
Left ventricular assist device.

Simple item page
dc.contributor.authorJiménez-Navarro, Manuel
dc.contributor.authorMolero, Encarnación
dc.contributor.authorTeresa, Eduardo de
dc.contributor.authoraffiliation[Jiménez-Navarro,M; Molero,E; Teresa,E de] Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.es
dc.date.accessioned2015-11-16T09:23:22Z
dc.date.available2015-11-16T09:23:22Z
dc.date.issued2002-03-28
dc.description.abstractTo the Editor: The value of angiotensin-converting– enzyme (ACE) inhibitors, beta-blockers, and spironolactone has been well established by the results of numerous clinical trials. About 70 percent of the patients described by Rose et al. were treated with ACE inhibitors or angiotensin II–receptor antagonists; 35 to 40 percent received spironolactone, and only about 20 percent received beta-blockers. Thus, this population cannot have been considered to be optimally treated from the point of view of medical therapy.es
dc.description.versionYeses
dc.identifier.citationJiménez-Navarro M, Molero E, Teresa E de. Left ventricular assist device. N. Engl. J. Med.. 2002; 346(13):1023-5; author reply 1023-5es
dc.identifier.essn1533-4406
dc.identifier.issn0028-4793
dc.identifier.pmid11924655
dc.identifier.urihttp://hdl.handle.net/10668/2053
dc.journal.titleThe New England Journal of Medicine
dc.language.isoen
dc.publisherMassachusetts Medical Societyes
dc.relation.publisherversionhttp://www.nejm.org/doi/full/10.1056/NEJM200203283461313es
dc.rights.accessRightsopen access
dc.subjectInhibidores de la enzima convertidora de angiotensinaes
dc.subjectInsuficiencia cardíacaes
dc.subjectCorazón Auxiliares
dc.subjectAntagonistas Adrenérgicos betaes
dc.subjectEspironolactonaes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors::Angiotensin-Converting Enzyme Inhibitorses
dc.subject.meshMedical Subject Headings::Diseases::Cardiovascular Diseases::Heart Diseases::Heart Failurees
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Assisted Circulation::Heart-Assist Deviceses
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Lactones::Spironolactonees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Adrenergic Agents::Adrenergic Antagonists::Adrenergic beta-Antagonistses
dc.titleLeft ventricular assist device.es
dc.typeletter
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Jimenez_Left.pdf
Size:
80.94 KB
Format:
Adobe Portable Document Format
Description:
Carta publicada
Download

Collections

SAS - Hospital Universitario Virgen de la Victoria

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía